CTOs on the Move

BridgeHealth

www.bridgehealth.com

 
BridgeHealth connects people with the nation`s best surgical care for a better experience, better outcomes, and better value. We offer a value-based approach to surgical care for self-insured plan sponsors and their members, saving them an average of 30% to 50% on procedures compared with PPO rates. BridgeHealth`s nationwide Centers of Excellence focus on quality outcomes and provide pre-negotiated bundled case rates for a broad scope of surgical procedures, including musculoskeletal, neurological, general surgery, cardiac, bariatric, and women`s health. BridgeHealth contracts with hospital providers who rank in the top quartile for their clinical specialty, based on outcomes and other objective ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kris Jamsa
 Chief Technology Officer Profile

Funding

BridgeHealth raised $40M on 10/22/2020

Similar Companies

Oxford PharmaGenesis

Oxford PharmaGenesis is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nu-Med Plus

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to concentrate on high growth potential markets where there are visible, distinct needs recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use.

Biotics Research Corporation

Biotics Research Corporation is a Rosenberg, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Conceptual Counseling Inc

Conceptual Counseling Inc is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.